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Purpose
Corticosteroids (CS) are commonly used for the treatment
of children with rheumatic diseases (RD) at presentation
or relapse; the dose is reduced or discontinued with dis-
ease improvement. The aim of this study was to examine
the dose-related effect of CS on the timing of peak body
mass index (BMI) in children with RD and the degree of
restitution to pre-CS BMI.
Methods
We used data from the Steroid Associated Osteoporosis
in the Pediatric Population (STOPP) Canadian Incidence
Study for patients >age 2 years with RD from enrolment
to 18 months after CS initiation. We grouped patients
according to clinically meaningful CS starting doses
(combining total IV and oral CS dose in the first 2
weeks and calculated as mg of prednisone-equivalent
per kg of body weight per day). CS starting doses were
defined as high (≥ 1.00 mg/kg/d), moderate (0.20 to 0.99
mg/kg/d) and low (<0.20 mg/kg/d to a maximum of
7.50 mg/d). We developed a mixed effects growth curve
model as a non-parametric estimate of average BMI z-
score trajectory, estimated using cubic splines, a type of
robust polynomial regression.
Results
Data was available for 114 of 136 subjects (65.4% female).
Median study-entry age was 10 years (inter-quartile
range 6-14 years). Diagnoses were: juvenile idiopathic
arthritis (38.2%), systemic lupus erythematosus (15.4%),
juvenile dermatomyositis (22.1%), and other RD (24.3%).
CS starting dose was high in 57.2%, moderate in 39.8%
and low in 3%. BMI peaked at about 4 months after CS
initiation (Figure 1). The BMI z-score curves for the
moderate and high CS groups were significantly different
(p<0.001). The low dose group had too few subjects for
analysis. Overall, 49.1% (95% CI, 39.7%, 58.6%) of sub-
jects failed to return to within +0.25 SD of their baseline
z-scores at 18 months. A similar percentage of patients
in the moderate and high CS starting dose groups failed
to return to within +0.25 SD of their baseline z-scores at
18 months (45.2% vs 51.1%, p=0.8). Contrary to our
hypothesis, higher baseline BMI did not reduce the likeli-
hood of returning to baseline BMI z-scores.
Conclusion
In children with RD treated with moderate to high doses
of CS, BMI increases and peaks at 4 months independent
of CS starting dose. High CS starting doses produce
higher peaks, but do not change the general shape of the
BMI trajectory after CS initiation compared to moderate
CS starting doses. Approximately half of all patients
started on CS for RD fail to return to within +0.25 SD of
their baseline BMI 18 months later. Funding: CIHR, UBC
Clinician Investigator, Frederick Banting and Charles
Best Canada Graduate Scholarships (CIHR).
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Figure 1 BMI z-score trajectories for children with RD according to CD starting dose
Shiff et al. Pediatric Rheumatology 2012, 10(Suppl 1):A11
http://www.ped-rheum.com/content/10/S1/A11
Page 2 of 2
